Mannkind (MNKD) Net Income towards Common Stockholders (2010 - 2026)
Mannkind (MNKD) reported Net Income towards Common Stockholders of -$16.6 million for Q1 2026, down 226.3% year-over-year from $13.2 million in Q1 2025, and up 20.47% quarter-over-quarter from -$20.9 million in Q4 2025.
Mannkind (MNKD) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Mannkind (MNKD) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$16.6 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at -$16.6 million, down 226.3% year-over-year; the trailing twelve-month figure through Mar 2026 was -$28.9 million (down 195.87% YoY), and the FY2025 annual result was $914000.0, down 96.69% from the prior year.
- Net Income towards Common Stockholders climbed to -$16.6 million in Q1 2026 per MNKD's latest filing, from -$20.9 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $13.2 million in Q1 2025 and troughed at -$29.0 million in Q2 2022.
- A 5-year average of -$5.0 million and a median of -$2.0 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders soared 427.01% in 2024, then sank 381.82% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$17.9 million in 2022, then jumped by 107.84% to $1.4 million in 2023, then soared by 427.01% to $7.4 million in 2024, then slumped by 381.82% to -$20.9 million in 2025, then gained by 20.47% to -$16.6 million in 2026.
- Business Quant data shows MNKD's Net Income towards Common Stockholders at -$16.6 million in Q1 2026, -$20.9 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -14.46 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | -3.63 Mn |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -56.48 Mn |
| 10 | Mannkind | 1.13 Bn | 995.19 Mn | 82.66 Mn | -16.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.62 Mn |
| Dec 31, 2025 | -20.90 Mn |
| Sep 30, 2025 | 7.98 Mn |
| Jun 30, 2025 | 668,000.00 |
| Mar 31, 2025 | 13.16 Mn |
| Dec 31, 2024 | 7.42 Mn |
| Sep 30, 2024 | 11.55 Mn |
| Jun 30, 2024 | -2.01 Mn |
| Mar 31, 2024 | 10.63 Mn |
| Dec 31, 2023 | 1.41 Mn |
| Sep 30, 2023 | 3.58 Mn |
| Jun 30, 2023 | -5.27 Mn |
| Mar 31, 2023 | -9.80 Mn |
| Dec 31, 2022 | -17.95 Mn |
| Sep 30, 2022 | -14.43 Mn |
| Jun 30, 2022 | -29.02 Mn |
| Mar 31, 2022 | -26.00 Mn |
| Dec 31, 2021 | -28.06 Mn |
| Sep 30, 2021 | -4.43 Mn |
| Jun 30, 2021 | -35.52 Mn |